Clearside Biomedical names industry veteran, Dr. Thomas Ciulla, as CMO
Clearside Biomedical (NASDAQ:CLSD) appointed Dr. Thomas A. Ciulla, a board certified ophthalmologist and retinal specialist, as chief medical officer.
Dr. Ciulla has more than 27 years of clinical practice, academic and executive management experience within the global ophthalmic industry. Prior to joining Clearside, he was VP of ophthalmic strategy at Spark Therapeutics, where he led the medical strategy to support development and commercialization of Luxturna, the first FDA-approved gene therapy for a genetic disease.
Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, the largest U.S. medical school. He also serves on the board of Midwest Eye Institute and is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology.
Dr. Ciulla also has held numerous leadership roles in more than 100 national clinical trials, including CATT and registration trials for nearly all retinal therapeutics currently approved by the FDA.
“In addition to being a skilled ophthalmologist and retinal specialist, Tom is well recognized for his ability to serve as a strong liaison between ophthalmic biopharmaceutical developers and their stakeholders, as well as for his passionate commitment to ensuring clinical programs are designed to meet the needs of both clinicians and patients,” Daniel White, president and CEO of Clearside, said in a statement.
“I have great confidence that he will play a key role in the continued advancement of both our late-stage pipeline and our non-clinical programs in areas such as gene therapy and choroidal drug delivery,” he added.